导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.58% | 2959/4773 |
| 近一周 | -2.16% | 1353/5462 |
| 近一月 | -4.07% | 2191/5421 |
| 近一季 | -7.43% | 2403/5209 |
| 近半年 | 0.34% | 1171/4920 |
| 近一年 | -0.21% | 2689/4366 |
| 近两年 | 39.94% | 1901/2954 |
| 近三年 | 28.64% | 1109/2253 |
| 成立以来 | 75.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.45% 3630/4961 |
9.60% 2475/5312 |
- - |
- - |
| 2025 | 18.39% 2323/4813 |
-0.76% 2396/3635 |
2.71% 1405/4076 |
13.45% 2994/4524 |
2.37% 975/4813 |
| 2024 | 20.87% 432/3463 |
5.27% 381/2808 |
0.44% 607/3014 |
18.23% 1038/3129 |
-3.31% 2323/3463 |
| 2023 | -7.69% 939/2656 |
1.84% 1501/2280 |
-3.87% 937/2385 |
1.53% 301/2515 |
-7.13% 2063/2655 |
| 2022 | -15.03% 405/2207 |
-12.63% 642/1919 |
9.81% 268/2016 |
-12.41% 704/2113 |
1.11% 1386/2208 |
| 2021 | -8.75% 1057/1822 |
-2.03% 572/1255 |
2.24% 1010/1330 |
-10.33% 1220/1466 |
1.60% 866/1822 |
| 2020 | 36.10% 404/1250 |
-10.65% 798/1028 |
13.82% 590/1067 |
13.80% 308/1164 |
17.59% 118/1184 |
| 2019 | 45.68% 147/1092 |
25.78% 445/754 |
4.92% 19/804 |
2.06% 329/850 |
8.17% 343/918 |
| 2018 | -19.75% 177/834 |
- - |
- - |
- - |
-12.65% 467/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实富时中国A50ETF VS. 长安沪深300非周期A(740101) |